Viking Therapeutics, Dragonfly Energy, and other leading companies are leveraging artificial intelligence (AI) to drive significant advancements in the health and energy sectors. These breakthroughs are not only reshaping their respective industries but also setting new standards for innovation and collaboration.
Viking Therapeutics, a clinical-stage biopharmaceutical company, announces positive top-line results from its Phase 2 trial. The study, which evaluates the safety and efficacy of VK2809, a novel liver-targeted therapy, demonstrates significant improvements in key biomarkers. This success paves the way for further development and potential market entry.
The PainReform and DeepSolar partnership is accepted into the prestigious NVIDIA Connect program. This initiative aims to accelerate the development of AI-driven solutions for pain management and renewable energy. The collaboration leverages NVIDIA's advanced computing platforms to enhance the efficiency and effectiveness of their technologies.
Gaxos Labs introduces Art-Gen, a powerful AI platform designed to create high-quality images and videos. This innovative tool utilizes deep learning algorithms to generate visually stunning content, revolutionizing the creative industry. Art-Gen is expected to be a game-changer for artists, designers, and content creators.
VCI Global, a leading technology investment firm, secures a US$2 billion partnership with a sovereign wealth fund. This significant investment will support the development and deployment of AI-driven solutions across various sectors, including healthcare, energy, and finance. The partnership aims to drive innovation and create long-term value.
Dragonfly Energy and Airstream® expand their partnership to develop advanced battery solutions for recreational vehicles (RVs). The collaboration leverages AI to optimize battery performance, extend lifespan, and reduce environmental impact. This partnership is a significant step towards sustainable and efficient energy solutions in the RV industry.
BioXcel Therapeutics achieves a critical milestone with the database lock in its SERENITY At-Home study. This study evaluates the use of AI-powered digital therapeutics for the treatment of agitation in patients with dementia. The successful completion of this phase marks a significant step towards the commercialization of these innovative solutions.
Subscribe to our newsletter for the latest AI news, tutorials, and expert insights delivered directly to your inbox.
We respect your privacy. Unsubscribe at any time.
Comments (0)
Add a Comment